Search Results

TaiGen Successfully Completes TG-1000 Phase III Study

• Source: PR Newswire. April 17, 2024

Record details

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication.

• Source: PR Newswire. October 26, 2022

Record details

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19.

• Source: PR Newswire. October 9, 2022

Record details

Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023.

• Source: PR Newswire. February 20, 2023

Record details

Coronavirus on Trial.

• Authors : Routh, Jennifer

• Source: USA Today (Magazine). March, 2020, Vol. 148 Issue 2898, p28, 3 p.

Record details

FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID.

• Source: PR Newswire. August 8, 2022

Record details

Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication.

• Source: PR Newswire. March 30, 2022

Record details

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication.

• Source: PR Newswire. January 10, 2022

Record details

Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments.

• Source: PR Newswire. November 22, 2021

Record details

SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing.

• Source: PR Newswire. November 19, 2021

Record details